濮阳东方妇科技术非常专业(濮阳东方医院男科治疗阳痿口碑非常好) (今日更新中)

The collective mourning of a community shaken by a brazen act of violence in a synagogue will continue Tuesday as funerals are held for three of the victims of what the Anti-Defamation League said was the deadliest attack against Jews in US history.On Monday night, blue light washed over the night sky as buildings across Pittsburgh were illuminated in tribute to the 11 worshippers killed Saturday when a gunman stormed the Tree of Life synagogue there.The close-knit community of Squirrel Hill, where the shootings took place, will first bid farewell to brothers Cecil and David Rosenthal and Dr. Jerry Rabinowitz, according to CNN affiliate WTAE.The funerals coincide with a visit from President Donald Trump, who will travel to Pittsburgh Tuesday despite a request from the city's mayor to hold off on visiting.  830

The Department of Homeland Security is on heightened alert, watching for any election security issues.In the last week of October, hackers targeted at least six states, attempting to get into their voter databases and election security systems, according to the Boston Globe. Some states reported they had to block more than 50,000 log-in attempts that came from foreign countries.“The worst-case scenario is somehow a system is slowed down or brought down, or perhaps there’s some problems on election day, where voters have to wait longer,” says John Fortier, with the Bipartisan Policy Center. “But there are backup procedures and there are ways of recovering from this.”On Tuesday, the Department of Homeland Security reassured voters that their ballots are safe.“We have no indication of compromise of our nation’s election infrastructure that would prevent voting, change vote counts, or disrupt the ability to tally votes,” said their statement in part.“At this stage in the election, we’re not expecting it, certainly not to effect votes, and secondly there are lots of procedures to recover from this,” Fortier explains. “If there is a problem, there is a backup, both for voters and election administrators.”For now, the bigger concern has become misinformation online, including attempts to cause chaos and manipulate public opinion.Read the joint statement released by the Department of Homeland Security and Department of Justice in its entirety below:“Our agencies have been working in unprecedented ways to combat influence efforts and to support state and local officials in securing our elections, including efforts to harden election infrastructure against interference. Our goal is clear: ensure every vote is counted and counted correctly. At this time we have no indication of compromise of our nation’s election infrastructure that would prevent voting, change vote counts, or disrupt the ability to tally votes.”“But Americans should be aware that foreign actors – and Russia in particular – continue to try to influence public sentiment and voter perceptions through actions intended to sow discord. They can do this by spreading false information about political processes and candidates, lying about their own interference activities, disseminating propaganda on social media, and through other tactics. The American public can mitigate these efforts by remaining informed, reporting suspicious activity, and being vigilant consumers of information, as discussed below.”“The United States will not tolerate foreign interference in our elections from Russia, China, Iran, or other nations. As noted in a  joint statement on October 19, 2018, such actions are a threat to our democracy, and identifying and preventing this interference is one of our highest priorities. On September 12, President Trump signed an executive order that makes clear the U.S. government will not hesitate to defend our electoral processes or punish those who attempt to undermine them.” “Our agencies have been making preparations for nearly two years in advance of these elections and are closely engaged with officials on the ground to help them ensure the voting process is secure. Americans can rest assured that we will continue to stay focused on this mission long after polls have closed.” 3337

The FBI has released new pictures of a North Carolina teenager who was abducted outside her home, and it is urging people to take a close look at surveillance video it says shows a suspect.Someone drove away with 13-year-old Hania Aguilar in an SUV that had been idling outside her Lumberton home Monday morning before school, authorities said, prompting police to issue an Amber Alert for her.The stolen SUV was found abandoned Thursday morning less than 10 miles from Hania's home at the Rosewood Mobile Home Park, authorities said.A missing persons poster that the FBI released late this week contains more pictures of Hania than were released initially.A reward for information that leads to her has risen to ,000, Lumberton police Chief Michael McNeill said Friday.The FBI has asked the public to examine video it says shows a man walking near Hania's home. 873

The City of Glendale plans to vote on adding a permanent American flag to the top of Thunderbird Mountain. The Glendale Chamber Military and Veterans Affairs Committee sent a proposal to the city council asking to erect a flag. The committee will also manage it. Thunderbird Mountain falls within a conservation park, which means it is to be left as is. The picnic tables, garbage cans, and signage are all a part of the city's master plan, which is why they are allowed in the park. "We want people to enjoy it but not to disturb the wildlife the plants and not erect any structures in the park either, at least if they're not part of the master plan," said Vice-Mayor Lauren Tolmachoff. She is one of the council members voting to hold off on the change. "Not everybody on the council felt there was a conservation national park because there are signs and roads, and I disagree with that," she said. "You know there are roads in national parks, but they are still to be preserved and protected."No word on when the council will take an official vote, but it will likely be before the end of June.  1153

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报